GLAXO - Fundamental Analysis: Financial Health & Valuation
← Back to ListKey Parameters
⭐ Fundamental Rating: 3.2
✅ Positive
GlaxoSmithKline Pharma demonstrates robust profitability with a high ROCE and consistent PAT growth, alongside a decent dividend yield and minimal debt. The company’s current price appears relatively low compared to its P/E ratio within the industry.
⚠️ Limitation
Despite strong financial metrics, the PEG ratio of 3.16 indicates an overvaluation relative to earnings growth expectations. Furthermore, recent negative news regarding sell ratings from marketsmojo suggests potential headwinds for future performance.
📉 Company Negative News
Marketsmojo reports a 'Sell' rating on Glaxosmithkline Pharmaceuticals Ltd, reflecting concerns about future prospects and potentially indicating short-term downside pressure. Whalesbook highlights a profit jump, but doesn’t disclose the underlying growth drivers or future outlook.
📈 Company Positive News
None found
🏭 Industry
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory environments, and significant competition. Innovation and patent protection are key to sustained success within this sector, making companies like GlaxoSmithKline Pharma reliant on successful drug development and commercialization strategies.
🧾 Conclusion
Given its current price of 2,650 ₹, an entry zone between 2,300 ₹ – 2,450 ₹ presents a potential undervaluation considering the company’s strong financial performance and industry context. Long-term holding guidance suggests focusing on developments in key therapeutic areas and maintaining a cautious approach due to the sell rating. The stock warrants consideration as a long-term hold with diligent monitoring of industry trends and company-specific news, aiming for a potential upside of 15%-20% over 3-5 years.